课题基金 / 基金详情

项目摘要

项目成果

Peter John Bex的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Glaucoma is the second leading cause of blindness in the developed world and causes progressive loss of the peripheral visual field. While visual loss caused by glaucoma is currently irreversible, clinical intervention is most effective if the disease is caught at an early stage, when catastrophic field loss can be averted. Unfortunately existing screening techniques can only detect glaucoma once significant visual impairment has occurred. Although visual deficits in glaucoma are thought to be attributable to programmed cell death (apoptosis) of retinal ganglion cells (RGCs) it is now clear that cell-death is the endpoint of a gradual deterioration in RGC-function. Effective diagnostics cannot wait for cell death, but must measure a behavioral impact of RGC dysfunction. When screening fails, the clinician is particularly reliant on the patients self-diagnosing. Unfortunately more than 50% of people who have diagnosable glaucoma are unaware of it. This, along with poor screening sensitivity has long-term implications for the effective management of an increasingly prevalent disease. This proposal assesses a more efficient and more sensitive motion screening technique that may help detect RGC dysfunction earlier, facilitating prompt clinical intervention to slow the progression of glaucoma. We examine binocular vision, filling-in and compensatory eye movements that may obscure detection of progressive visual impairment and prevent patients from self-diagnosing at an earlier stage of the disease. The overall aim of this proposal is to identify signs of glaucoma that may help bring patients to clinic before catastrophic glaucomatous visual field loss has occurred. Such early intervention allows clinical management of glaucoma to be most effective and so relieves the burden of visual impairment. PUBLIC HEALTH RELEVANCE: Glaucoma is the second leading cause of blindness in the developed world and its incidence is set to rise as the population ages. While visual loss caused by glaucoma is currently irreversible, clinical intervention is most effective if the disease is detected and treated at an early stage, when catastrophic field loss can be averted. The proposed program of research develops new diagnostics that are sensitive to the early stages of neuro-degeneration in glaucoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ARBi - Assessment and Rehabilitation of Binocular Sensorimotor Disorders
  • 批准号:
    10559543
  • 项目类别:
  • 资助金额:
    $52.61万
  • 财政年份:
    2022
  • 负责人:
    Peter John Bex
  • 依托单位:
Eye Movement Rehabilitation in Low Vision Patients
  • 批准号:
    10362666
  • 项目类别:
  • 资助金额:
    $35.86万
  • 财政年份:
    2019
  • 负责人:
    Peter John Bex
  • 依托单位:
Eye Movement Rehabilitation in Low Vision Patients
  • 批准号:
    10612338
  • 项目类别:
  • 资助金额:
    $36.97万
  • 财政年份:
    2019
  • 负责人:
    Peter John Bex
  • 依托单位:
Enhancement of Dynamic Media for Visually-Impaired People
  • 批准号:
    8320302
  • 项目类别:
  • 资助金额:
    $46.09万
  • 财政年份:
    2009
  • 负责人:
    Peter John Bex
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: